Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
$0.06
$0.49
$0.05
▼
$1.05
$440K-0.821,073 shs11 shs
BiomX Inc. stock logo
PHGE
BiomX
$0.14
+0.7%		$0.25
$0.12
▼
$12.29
$1.58M1.351.40 million shs627,578 shs
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$2.88
-8.0%		$2.64
$2.15
▼
$16.80
$1.62M2.0886,594 shs129,397 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
0.00%0.00%-90.95%-91.71%-93.20%
BiomX Inc. stock logo
PHGE
BiomX
-2.47%-7.20%-29.05%-91.72%-98.71%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00%0.00%0.00%0.00%+20.00%
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-2.80%+37.16%+36.09%-35.20%-80.44%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
$0.06
$0.49
$0.05
▼
$1.05
$440K-0.821,073 shs11 shs
BiomX Inc. stock logo
PHGE
BiomX
$0.14
+0.7%		$0.25
$0.12
▼
$12.29
$1.58M1.351.40 million shs627,578 shs
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
$0.00
$0.00
$0.00
▼
$0.00
N/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$2.88
-8.0%		$2.64
$2.15
▼
$16.80
$1.62M2.0886,594 shs129,397 shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
0.00%0.00%-90.95%-91.71%-93.20%
BiomX Inc. stock logo
PHGE
BiomX
-2.47%-7.20%-29.05%-91.72%-98.71%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00%0.00%0.00%0.00%+20.00%
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-2.80%+37.16%+36.09%-35.20%-80.44%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
0.00
N/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
2.00
Hold$26.0019,159.26% Upside
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
0.00
N/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest CPMV, RSPI, SCNI, and PHGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2026
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/AN/AN/AN/A($1.08) per shareN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/A$0.94 per shareN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
$1.31M1.14N/AN/A$7.77 per share0.37
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
-$690K-$0.09N/AN/AN/AN/AN/A-3,108.08%N/A
BiomX Inc. stock logo
PHGE
BiomX
-$36.20M-$3.21N/AN/AN/AN/AN/A-165.38%11/11/2026 (Estimated)
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/A-$0.02N/AN/AN/AN/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
-$8.31M-$1.06N/AN/AN/AN/AN/AN/AN/A

Latest CPMV, RSPI, SCNI, and PHGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/24/2026Q2 2026
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
N/A-$0.74N/A-$0.74N/A$0.46 million
8/19/2026Q2 2026
BiomX Inc. stock logo
PHGE
BiomX
N/A-$0.37N/A-$0.37N/A$0.33 million
8/14/2026Q2 2026
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/A-$0.02N/A-$0.02N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
0.02
0.24
0.24
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/AN/AN/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
0.05
1.35
1.35

Institutional Ownership

CompanyInstitutional Ownership
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
N/A
BiomX Inc. stock logo
PHGE
BiomX
40.57%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
N/A
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
58.41%

Insider Ownership

CompanyInsider Ownership
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
80.99%
BiomX Inc. stock logo
PHGE
BiomX
0.23%
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
50.03%
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
6.03%
CompanyEmployeesShares OutstandingFree FloatOptionable
Mosaic ImmunoEngineering Inc. stock logo
CPMV
Mosaic ImmunoEngineering
37.24 million1.38 millionNot Optionable
BiomX Inc. stock logo
PHGE
BiomX
12011.80 million11.77 millionN/A
Cortex Pharmaceuticals Inc. stock logo
RSPI
Cortex Pharmaceuticals
2949.46 million474.45 millionNot Optionable
Scinai Immunotherapeutics Ltd. Sponsored ADR stock logo
SCNI
Scinai Immunotherapeutics
20520,000486,000Not Optionable

Recent News About These Companies

Scinai Immunotherapeutics Ltd (SCNI) Stock Price, Quote, News & History
August 25 at 10:03 AM  |  benzinga.comhttps://www.benzinga.com/quote/SCNI
Scinai Immunotherapeutics Ltd.: Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
August 24 at 1:38 PM  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69389239-scinai-immunotherapeutics-ltd-scinai-reports-first-half-2026-corporate-highlights-and-results-with-spotlight-on-growing-cdmo-momentum-008.htm
Scinai Reports First Half 2026 Corporate Highlights and Results with Spotlight on Growing CDMO Momentum
August 24 at 7:00 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-reports-first-half-2026-corporate-highlights-and-results-with-spotlight-on-growing-cdmo-momentum-302858235.html
Scinai Immunotherapeutics Ltd. Sponsored ADR
August 14, 2026  |  edition.cnn.comhttps://edition.cnn.com/markets/stocks/SCNI
Scinai Immunotherapeutics Ltd.: Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
August 10, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69264226-scinai-immunotherapeutics-ltd-scinai-strengthens-cdmo-leadership-with-appointment-of-eran-kuratz-as-head-of-supply-chain-and-business-process-admini-008.htm
Scinai Strengthens CDMO Leadership with Appointment of Eran Kuratz as Head of Supply Chain and Business Process Administration
August 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-strengthens-cdmo-leadership-with-appointment-of-eran-kuratz-as-head-of-supply-chain-and-business-process-administration-302847061.html
Scinai Reports First Quarter 2026 Financial Results and Provides Corporate Update Highlighting Expansion of CDMO Platform and Advancement of Strategic Growth Initiatives
June 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-reports-first-quarter-2026-financial-results-and-provides-corporate-update-highlighting-expansion-of-cdmo-platform-and-advancement-of-strategic-growth-initiatives-302796684.html
Scinai Biopharma Services Appoints Eilon Elmalem as Site Head of Yavne CDMO Facility
May 20, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-biopharma-services-appoints-eilon-elmalem-as-site-head-of-yavne-cdmo-facility-302777462.html
Scinai Immunotherapeutics to Lead Strategic Roundtable Discussion on Oral Therapies and the Future of Biologics at the 7th Dermatology Drug Development Summit Europe
May 15, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-immunotherapeutics-to-lead-strategic-roundtable-discussion-on-oral-therapies-and-the-future-of-biologics-at-the-7th-dermatology-drug-development-summit-europe-302773524.html
Scinai Immunotherapeutics Announces $2.61 Million Private Placement Financing
April 24, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-immunotherapeutics-announces-2-61-million-private-placement-financing-302752848.html
Scinai Completes Strategic Reorganization to Establish Dedicated CDMO Platform and Lean R&D Structure; Outlines 2026 Priorities
April 6, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-completes-strategic-reorganization-to-establish-dedicated-cdmo-platform-and-lean-rd-structure-outlines-2026-priorities-302734595.html
Scinai Reports Full-Year 2025 Results, with CDMO Revenues Doubling and Strategic Expansion Through Recipharm Collaboration
April 1, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-reports-full-year-2025-results-with-cdmo-revenues-doubling-and-strategic-expansion-through-recipharm-collaboration-302731295.html
Scinai Immunotherapeutics Highlights Expanded CDMO Platform and Immunology Pipeline at BIO-Europe Spring® 2026
March 19, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-immunotherapeutics-highlights-expanded-cdmo-platform-and-immunology-pipeline-at-bio-europe-spring-2026-302718695.html
Scinai Immunotherapeutics Receives Nasdaq Notification Regarding Minimum Bid Price
March 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-immunotherapeutics-receives-nasdaq-notification-regarding-minimum-bid-price-302714995.html
Scinai Signs Second Amendment to PinCell Option Agreement and Submits Revised €12 Million Non-Dilutive FENG Application to Advance PC111 Through Human Proof of Concept
March 2, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-signs-second-amendment-to-pincell-option-agreement-and-submits-revised-12-million-non-dilutive-feng-application-to-advance-pc111-through-human-proof-of-concept-302701108.html
Scinai Announces Expanded Israel Innovation Authority Support for Robotic Aseptic Fill & Finish Platform
February 25, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-announces-expanded-israel-innovation-authority-support-for-robotic-aseptic-fill--finish-platform-302697055.html
Scinai Announces Completion of Acquisition of Recipharm Israel Ltd. and Strategic Commercial Collaboration with Recipharm
February 17, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-announces-completion-of-acquisition-of-recipharm-israel-ltd-and-strategic-commercial-collaboration-with-recipharm-302689449.html
Scinai CEO Amir Reichman to Co-Lead Manufacturers Association Biopharma Manufacturing Roundtable at HealthIL
January 7, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-ceo-amir-reichman-to-co-lead-manufacturers-association-biopharma-manufacturing-roundtable-at-healthil-302655108.html
Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) Sees Large Drop in Short Interest
January 2, 2026  |  defenseworld.netD
Scinai Reports Nine-Month 2025 Results as CDMO Growth Continues and NanoAbs Pipeline Advances
December 2, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/scinai-reports-nine-month-2025-results-as-cdmo-growth-continues-and-nanoabs-pipeline-advances-302630483.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Mosaic ImmunoEngineering stock logo

Mosaic ImmunoEngineering OTCMKTS:CPMV

$0.06 0.00 (0.00%)
As of 08/24/2026

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

BiomX stock logo

BiomX NYSEAMERICAN:PHGE

$0.14 +0.00 (+0.67%)
As of 04:10 PM Eastern

BiomX Inc., a clinical-stage microbiome company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria. It targets bacteria that affect the appearance of skin, as well as chronic diseases, such as inflammatory bowel diseases (IBD), primary sclerosing cholangitis (PSC), cystic fibrosis (CF), atopic dermatitis, and colorectal cancer (CRC). It is developing BX004, a phage therapy for CF patients with chronic Pseudomonas aeruginosa respiratory infections that is in Phase 1b/2a clinical trials. The company's pipeline products also include BX005, a topical phage cocktail, which is in Phase 1/2 clinical study that targets Staphylococcus aureus (S. aureus), a bacteria associated with the manifestation of the disease. In addition, the company engages in the provision of colorectal cancer program that utilizes engineered phage with various payloads, which are administered intravenously to target Fusobacterium nucleatum bacteria residing within the tumor microenvironment. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.

Cortex Pharmaceuticals stock logo

Cortex Pharmaceuticals OTCMKTS:RSPI

$0.0018 0.00 (0.00%)
As of 08/21/2026

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. It has a research collaboration with University College London to the use of AMPAkines for the treatment of GRIA disorders. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

Scinai Immunotherapeutics stock logo

Scinai Immunotherapeutics NASDAQ:SCNI

$2.88 -0.25 (-7.99%)
Closing price 04:00 PM Eastern
Extended Trading
$2.96 +0.08 (+2.60%)
As of 05:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas